[
  {
    "title": "With Vivtex deal, Novo gains a chance at better oral obesity drugs",
    "link": "https://www.biopharmadive.com/news/vivtex-novo-nordisk-oral-obesity-drugs-biologics/812754/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-25T13:00:00.000Z",
    "summary": "The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of oral biologic medicines."
  },
  {
    "title": "Breaking down the health care talk in Trump’s State of the Union",
    "link": "https://www.statnews.com/2026/02/25/health-news-drug-pricing-trump-plan-hhs-concerns/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-25T12:51:18.000Z",
    "summary": "Trump touts lower drug costs, states sue HHS, and other can't miss health news of the day"
  },
  {
    "title": "BreezeBio banks $60M to make more precise genetic medicines",
    "link": "https://www.biopharmadive.com/news/breezebio-genedit-series-b-diabetes-autoimmune/812976/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-25T12:00:00.000Z",
    "summary": "The company has shed its former “GenEdit” name and strategy in favor of a plan to develop its own medicines, starting with a potential tolerance-inducing treatment for Type 1 diabetes."
  },
  {
    "title": "6 in 10 women will develop heart disease or stroke by 2050, heart association projects",
    "link": "https://www.statnews.com/2026/02/25/heart-disease-risk-forecasts-women-2050-projections/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-25T10:00:00.000Z",
    "summary": "“We're just setting up a generation of people to move through life, having their cardiovascular events earlier and more severe.\""
  },
  {
    "title": "Opinion: How dentists like me can help patients with substance use disorder",
    "link": "https://www.statnews.com/2026/02/25/dentists-substance-use-disorder-screening-opioids/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-25T09:30:00.000Z",
    "summary": "Dentistry has long been built on preventive care. It’s time to extend that preventive mindset to substance use."
  },
  {
    "title": "Opinion: The Rural Health Transformation Program could fail patients like mine",
    "link": "https://www.statnews.com/2026/02/25/rural-health-transformation-program-hospitals-innovation/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-25T09:30:00.000Z",
    "summary": "Maintaining the capacity to provide care close to home for rural patients is critical, but it’s under threat."
  },
  {
    "title": "STAT+: GSK picks up pulmonary hypertension drug with 35Pharma acquisition",
    "link": "https://www.statnews.com/2026/02/25/gsk-acquires-35pharma-pulmonary-hypertension/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-25T08:01:14.000Z",
    "summary": "GSK is buying the Canadian biotech 35Pharma, building up its base of medicines for lung diseases."
  },
  {
    "title": "Trump touts lower drug costs and anti-fraud measures in lengthy State of the Union",
    "link": "https://www.statnews.com/2026/02/24/trump-state-union-health-plan-drug-prices-maha/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-25T04:48:16.000Z",
    "summary": "At SOTU, Trump touted health care wins even as more than half of Americans say health care has become more unaffordable for them and their families."
  },
  {
    "title": "STAT+: Will Novo Nordisk’s slashing of obesity drug prices save patients’ money? It depends",
    "link": "https://www.statnews.com/2026/02/24/novo-nordisk-weight-loss-drug-price-cut-examined/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T19:41:15.000Z",
    "summary": "Will Novo Nordisk’s slashing of obesity drug prices save patients’ money or expand access? It depends."
  },
  {
    "title": "STAT+: Drugmakers lay out their legal arguments against Trump’s drug pricing experiments",
    "link": "https://www.statnews.com/2026/02/24/pharma-opposition-medicare-drug-price-pilot-programs-strategy-emerges/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T17:57:19.000Z",
    "summary": "Comments opposing Medicare's efforts to lower U.S. drug prices provide a roadmap to potential legal challenges ahead."
  },
  {
    "title": "Vir climbs on Astellas deal, study results for ‘masked’ T cell engager",
    "link": "https://www.biopharmadive.com/news/vir-astellas-masked-t-cell-engager-prostate-cancer-results/812950/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-24T17:18:43.000Z",
    "summary": "According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an infectious disease specialist before changing course."
  },
  {
    "title": "Novo to cut GLP-1 drug prices; Palvella soars on study data",
    "link": "https://www.biopharmadive.com/news/novo-price-cuts-palvella-gossamer-vanda-pfizer-china/812906/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-24T16:00:00.000Z",
    "summary": "Wegovy and Ozempic’s list prices will be reduced by as much as 50% effective next year. Elsewhere, Palvella’s market value surged past $1 billion while Pfizer nabbed rights to another obesity drug."
  },
  {
    "title": "STAT+: Novo reports ‘triple G’ obesity drug study results",
    "link": "https://www.statnews.com/2026/02/24/biotech-news-novo-nordisk-triple-g-obesity-results/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T14:30:06.000Z",
    "summary": "Fresh off a failed trial that sent its shares plummeting, Novo Nordisk said that one of its experimental obesity drugs helped patients lose nearly 20% of their weight after 24 weeks…"
  },
  {
    "title": "STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more",
    "link": "https://www.statnews.com/pharmalot/2026/02/24/fda-novo-obesity-wegovy-ozempic-novartis-jnj-bayer/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T14:23:12.000Z",
    "summary": "The Trump administration released detailed guidance for approving the first bespoke medicines crafted to treat individual patient mutations"
  },
  {
    "title": "Hepatitis B vaccine rates are dropping",
    "link": "https://www.statnews.com/2026/02/24/health-news-hep-b-vaccine-rates-drop/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T14:06:28.000Z",
    "summary": "After a period of growth, the percentage of newborns being vaccinated against hepatitis B has seen significant declines in the last couple years, research finds"
  },
  {
    "title": "STAT+: An AI startup floats FDA deregulation, using an obscure backdoor",
    "link": "https://www.statnews.com/2026/02/24/ai-startup-floats-fda-deregulation-via-backdoor-health-tech/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T14:03:21.000Z",
    "summary": "In this edition of STAT's Health Tech: An AI startup pushes for some AI-powered medical devices to be exempt from pre-market review, and other health tech news."
  },
  {
    "title": "Novo, searching for a spark, spotlights new data for three-pronged obesity drug",
    "link": "https://www.biopharmadive.com/news/novo-nordisk-ubt251-triple-g-obesity-drug-results/812926/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-24T13:05:00.000Z",
    "summary": "Novo’s answer to a closely watched Lilly drug spurred roughly 20% weight loss after 24 weeks in a Phase 2 trial, results one of its executives claimed to be “differentiating.”"
  },
  {
    "title": "Slate starts up with $130M and a headache drug from China",
    "link": "https://www.biopharmadive.com/news/slate-medicines-migraine-biotech-pacap-china-dartsbio/812859/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-24T12:30:00.000Z",
    "summary": "The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the onset of migraines."
  },
  {
    "title": "STAT+: Jeffrey Epstein’s tissue samples ignited a furor in the Harvard lab of George Church",
    "link": "https://www.statnews.com/2026/02/24/epstein-cell-line-george-church-harvard-personal-genome-project/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T09:30:00.000Z",
    "summary": "Exclusive: Harvard geneticist George Church knew more about Jeffrey Epstein's activities than he has previously said, before accepting new donations from the sex offender."
  },
  {
    "title": "STAT+: Digital twins, the holy grail of preventative health, are still only a ‘Frankensteinian proof of principle’",
    "link": "https://www.statnews.com/2026/02/24/digital-twins-health-care-hype-reality/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T09:30:00.000Z",
    "summary": "AI advances and new data on genomics, patient outcomes, and drug performance have pushed the idea of “digital twins” closer to reality than ever before."
  },
  {
    "title": "STAT+: New treatment approach could give IBD patients hope, and be a bonanza for drugmakers",
    "link": "https://www.statnews.com/2026/02/24/ibd-combination-therapy-race-abbvie-lilly-pfizer-merck-jnj/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T09:30:00.000Z",
    "summary": "New treatment approaches could give inflammatory bowel disease patients hope, and make drugmakers a bonanza."
  },
  {
    "title": "Opinion: It’s time for a new era of advocacy for physicians",
    "link": "https://www.statnews.com/2026/02/24/doctors-advocacy-aafp-lobbying-congress/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T09:30:00.000Z",
    "summary": "“Physicians are, by nature and necessity, advocates,” writes Sarah C. Nosal, president of the American Academy of Family Physicians."
  },
  {
    "title": "Opinion: STAT+: Optum CMO: Doctors must take responsibility for patient outcomes",
    "link": "https://www.statnews.com/2026/02/24/medicare-advantage-plans-doctors-risk-outcomes-optum-research/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T09:30:00.000Z",
    "summary": "“To critics of Medicare Advantage, these results scramble the debate,” writes Optum CMO Ken Cohen."
  },
  {
    "title": "STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding",
    "link": "https://www.statnews.com/2026/02/23/him-hers-earnings-2026-outlook-compounded-semaglutide/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-24T01:14:06.000Z",
    "summary": "In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line."
  },
  {
    "title": "FDA fleshes out new roadmap for testing personalized therapies",
    "link": "https://www.biopharmadive.com/news/fda-guidance-personalized-therapies-rare-diseases-hhs/812890/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T22:03:00.000Z",
    "summary": "At an event on Monday, the agency officially unveiled long-awaited draft guidance meant to help speed the development of bespoke treatments for extremely rare diseases."
  },
  {
    "title": "STAT+: Bayer sues J&J over ‘false and misleading claims’ about competing prostate cancer treatments",
    "link": "https://www.statnews.com/pharmalot/2026/02/23/bayer-jnj-prostate-cancer-false-advertising-lawsuit/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T19:34:43.000Z",
    "summary": "Bayer sued rival Johnson & Johnson for launching a “false advertising campaign” based on flawed data to wrongfully promote its drug as more effective."
  },
  {
    "title": "Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study",
    "link": "https://www.biopharmadive.com/news/novo-nordisk-cagrisema-zepbound-head-to-head-results/812810/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T17:22:33.000Z",
    "summary": "Shares fell by more than 15% on results showing study participants receiving Novo’s CagriSema lost less weight than those who took Lilly’s Zepbound."
  },
  {
    "title": "STAT+: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications",
    "link": "https://www.statnews.com/2026/02/23/fda-rare-disease-new-guidelines-plausible-mechanism-pathway/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-23T16:35:07.000Z",
    "summary": "The FDA expects a flood of applications for a new \"plausible mechanism pathway\" for approval of bespoke gene-editing treatments."
  },
  {
    "title": "FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-23T16:32:48.000Z",
    "summary": "The U.S. Food and Drug Administration today issued draft guidance for sponsors seeking approval for targeted individualized therapies by generating substantial evidence of effectiveness and safety…"
  },
  {
    "title": "Merck to split cancer, specialty drug businesses in leadership shakeup",
    "link": "https://www.biopharmadive.com/news/merck-cancer-specialty-split-business-pharmaceuticals/812805/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T13:38:28.000Z",
    "summary": "Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines."
  },
  {
    "title": "Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy",
    "link": "https://www.biopharmadive.com/news/gilead-arcellx-acquire-multiple-myeloma-cell-therapy-anito-cel/812798/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-23T12:49:00.000Z",
    "summary": "The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said."
  },
  {
    "title": "Clearing cholesterol combats secondary lymphoedema",
    "link": "https://www.nature.com/articles/d41573-026-00032-6",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-20T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "The pancreatic cancer drug market",
    "link": "https://www.nature.com/articles/d41573-026-00027-3",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-20T00:00:00.000Z",
    "summary": ""
  }
]
